BioGend Therapeutics Co., Ltd. received notification from the Thai FDA that "Revocart" was approved to obtain a Thai medical device license. The company received notification from the Thailand FDA that Revocart was approved to obtain a Thailand medical device license. The company will seek dealers in Thailand to be responsible for the local promotion and sales of Revocart.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37 TWD | +1.37% | +1.51% | -3.27% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.27% | 14Cr | |
+43.36% | 5.46TCr | |
-5.31% | 3.99TCr | |
+37.52% | 3.88TCr | |
+14.75% | 2.69TCr | |
-12.56% | 2.62TCr | |
-22.45% | 1.88TCr | |
+25.12% | 1.22TCr | |
+0.04% | 1.22TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- 6733 Stock
- News BioGend Therapeutics Co., Ltd.
- BioGend Therapeutics Co., Ltd. Receives Notification from the Thai FDA That Revocart to Obtains A Thai Medical Device License